Premium
Crosstalk between sphingolipids and vitamin D3: potential role in the nervous system
Author(s) -
GarciaGil Mercedes,
Pierucci Federica,
Vestri Ambra,
Meacci Elisabetta
Publication year - 2017
Publication title -
british journal of pharmacology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.432
H-Index - 211
eISSN - 1476-5381
pISSN - 0007-1188
DOI - 10.1111/bph.13726
Subject(s) - sphingolipid , fingolimod , sphingosine , crosstalk , microbiology and biotechnology , sphingosine 1 phosphate , ceramide , biology , lipid signaling , sphingosine kinase , signal transduction , chemistry , neuroscience , biochemistry , multiple sclerosis , receptor , immunology , apoptosis , physics , optics
Sphingolipids are both structural and bioactive compounds. In particular, ceramide and sphingosine 1‐phosphate regulate cell fate, inflammation and excitability. 1‐α,25‐dihydroxyvitamin D3 (1,25(OH) 2 D 3 ) is known to play an important physiological role in growth and differentiation in a variety of cell types, including neural cells, through genomic actions mediated by its specific receptor, and non‐genomic effects that result in the activation of specific signalling pathways. 1,25(OH) 2 D 3 and sphingolipids, in particular sphingosine 1‐phosphate, share many common effectors, including calcium regulation, growth factors and inflammatory cytokines, but it is still not known whether they can act synergistically. Alterations in the signalling and concentrations of sphingolipids and 1,25(OH) 2 D 3 have been found in neurodegenerative diseases and fingolimod, a structural analogue of sphingosine, has been approved for the treatment of multiple sclerosis. This review, after a brief description of the role of sphingolipids and 1,25(OH) 2 D 3 , will focus on the potential crosstalk between sphingolipids and 1,25(OH) 2 D 3 in neural cells.